Mobile

A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 in patients diagnosed with Low and INT-1 risk Myelodysplastic Syndrome (MDS) and transfusion-de...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003971-11

A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 in patients diagnosed with Low and INT-1 risk Myelodysplastic Syndrome (MDS) and transfusion-dependent iron overload

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to evaluate if fixed starting doses of ICL670, dependent on transfusion history, and subsequent dose titration can provide clinically acceptable chelation among low and INT-1 risk MDS patients.

Critère d'inclusion

  • myelodysplastic syndrome and transfusion-dependent iron overload

Liens